Which hedge funds own BCRX? BIOCRYST PHARMACEUTICALS INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
11 of the hedge funds tracked by WhaleCreep disclosed a position in BCRX (BIOCRYST PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $260.6m in total. The largest holder by portfolio weight is RA Capital Management at 1.4% of its book. 3 managers opened a new position this quarter: Moore Capital Management, Tudor Investment, Point72 Asset Management LP. 1 exited: Farallon Capital Management.
11tracked managers holding
3opened this quarter
1exited this quarter
Which hedge funds hold BCRX? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| RA Capital Management | Q2 2026 | 1.4% | $158.3m | 15,827,186 | 0% | held |
| Moore Capital Management | Q2 2026 | 0.2% | $8.5m | 848,336 | – | new |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $25.3m | 2,530,290 | 226% | added |
| Millennium Management | Q2 2026 | 0.0% | $33.9m | 3,394,729 | 1708% | added |
| Bridgewater Associates | Q2 2026 | 0.0% | $4.9m | 491,057 | -23% | reduced |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $965.7k | 96,574 | 411% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $17.6m | 1,759,160 | 73% | added |
| Tudor Investment | Q2 2026 | 0.0% | $2.0m | 195,128 | – | new |
| Point72 Asset Management LP | Q2 2026 | 0.0% | $2.6m | 260,917 | – | new |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $4.1m | 408,529 | 35% | added |
| Marshall Wace | Q2 2026 | 0.0% | $2.5m | 252,764 | 3% | added |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Farallon Capital Management | 0.0% | $228.5k |
How has hedge fund ownership of BCRX changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 11 | $260.6m |
| Q1 2026 | 9 | $181.3m |
| Q4 2025 | 6 | $152.4m |
| Q3 2025 | 6 | $91.4m |
| Q2 2025 | 3 | $41.3m |
| Q1 2025 | 3 | $95.4m |
| Q4 2024 | 4 | $26.3m |
| Q3 2024 | 2 | $22.7m |
| Q2 2024 | 3 | $21.4m |
| Q1 2024 | 3 | $23.2m |
| Q4 2023 | 3 | $15.0m |
| Q3 2023 | 5 | $31.7m |
| Q2 2023 | 4 | $38.7m |
| Q1 2023 | 6 | $31.4m |
| Q4 2022 | 6 | $97.5m |
| Q3 2022 | 5 | $36.8m |
Counts every tracked manager that disclosed BCRX in that quarter's filing, including managers that have since stopped filing.